News

Andrew Morgenstern, OD, FAAO, FNAP, President and Co-founder of IKA, talked about his session at the meeting centering around the pediatric prevalence of keratoconus.

The implantable lenses can offer an advantage over laser surgery

According to ophthalmologists at the Colorado University School of Medicine, discussing mental well-being is a key part of effective treatment and improving care for patients.

Alternate methods of screening may lead to earlier diagnosis of disease.

Connecticut ophthalmologist Donald Salzberg, MD, was sentenced to a year and a day in prison for taking kickbacks in exchange for ordering medically unnecessary brain scans on patients. He was ordered to pay $1.34 million in restitution.

At this year's ARVO meeting, Irene Santiago Tierno, MS, talked with Ophthalmology Times about the paper she presented on how abnormal subendothelial matrix exacerbates choroidal endothelial cell death in early age-related macular degeneration.

At this year's ARVO meeting, Michael Chaglasian, OD, spoke with Ophthalmology Times about the paper he presented on the detection of glaucoma with a novel widefield imaging device combined with OCT

Dilsher S. Dhoot, MD, shared details about the Week 52 safety and efficacy data from the US phase 1 clinical trial of sustained-release axitinib hydrogel implant (OTX-TKI) for neovascular age-related macular degeneration at the 2024 Retina World Congress meeting in Fort Lauderdale, Florida.

The campaign will encourage, educate and empower the public to include vision and eye health as a part of their healthcare by asking them to share how eye care services and exams improved their vision and their daily lives.

Simply slowing disease progression is no longer enough.

At this year's ARVO meeting in Seattle, Washington, the Eye Care Network spoke with Niranchana Manivannan, PhD. She spoke about the poster presentation, "Feasibility and clinical efficacy of an OCT B-scan of interest tool."

At this year's ARVO meeting, Daniela Ferrara, MD, PhD, FASRS, presented a paper on predicting functional outcomes for different treatment durations of faricimab in Diabetic macular edema.

The trial evaluates OCU410ST, a modifier gene therapy candidate utilizing an AAV delivery platform for the retinal delivery of the RORA gene.

At this year's ARVO meeting, Edmund Tsui, MD, presented a paper on the analysis of anterior chamber inflammation through automated quantitative assessment of swept-source anterior segment OCT images.

Professor Paulo-Eduardo Stanga spoke with Modern Retina about a new wearable assistance device at the 2024 Retina World Congress meeting held in Fort Lauderdale, Florida

Promising innovations are not one-size-fits-all

Researchers at the University of Missouri School of Medicine have conducted a study in a humanized mouse model to show that infections can occur deep inside the eye by penetrating the blood-retinal barrier.

The Early Detection of Vision Impairment in Children (EDVI) Act would establish the first federal program to address children’s vision and eye health.

At this year's ARVO meeting, Roger Goldberg, MD, presented a paper on hard exudates and their resolution in patients with diabetic macular edema treated with either faricimab or 2 mg aflibercept.

GLOW2 follows the GLOW1 study in which tarcocimab-treated patients, over the 48-week study duration, saw 29-fold increased response rate in ≥ 2-step improvement in DRSS and 89% decreased risk of developing sight-threatening complications.

According to the company, GLOW2 is the second Phase 3 study of tarcocimab in diabetic retinopathy in which all patients on investigational therapy will receive tarcocimab on extended dosing intervals.

The submission for bevacizumab gamma (ONS-5010/LYTENAVA) follows a positive opinion from the CHMP in March.

Organization eyes green practices, shifting ophthalmology landscape.

This year at ARVO, Anand Swaroop, PhD, was awarded the Friedenwald Award Lecture 2024. He spoke with the Eye Care Network about this lecture and what the award meant to him.

This year at ARVO, Emily Chew, MD, was awarded the Proctor Award Lecture. She spoke with the Eye Care Network about this lecture and what the award meant to her.

The trial is a study of twice daily tanfanercept ophthalmic solution 0.25% and 1.0% and will leverage key insights from the concluded Phase III VELOS-3 study.

This year at ARVO, Daniel Saban PhD, was awarded the Cogan Award Lecture. He spoke with the Eye Care Network about this lecture and what the award meant to him.

Alcon agreed to acquire Belkin Vision and the Belkin Vision Eagle and plans to provide additional details when the deal is closed.